glp 1 and yeast infections infection Diabetes mellitus, vaginal microbiome sexual function: Outcomes in postmenopausal women GLP-1 | Summary

8 Future directions The advancement of GLP-1 receptor agonists is progressing towards more refined treatment strategies, with tirzepatide at the forefront of research as a dual GIP/GLP-1 receptor agonist (Nauck and DAlessio 2022)

GLP-1 medications can cause nausea, vomiting, and diarrhea, all of which contribute to fluid loss

Interpretation by a qualified provider is essential for clinical application

The goal is to help the patient understand that this therapy supports natural physiological processes and works alongside lifestyle changes

Patients who experience steady results may remain more engaged in their overall wellness plan, supporting outcomes that persist beyond initial weight loss phases